Fabry Disease: all 246 studies
Page 1 of 3. Open to participants first (56), then studies with results posted, then the rest; newest registration first within each.
- Therapeutic Implications of CMR Low Native T1 in Non-treated Non-hypertrophic Females With Fabry Disease (FD)Not yet recruitingNCT07872852Not applicable
- A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry DiseaseNot yet recruitingNCT07778667Phase 3
- Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302AvailableNCT07762638
- Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)RecruitingNCT07575347
- Quality of Life in Adults With Untreated Fabry Disease in Sweden (QoLUF)Enrolling by invitationNCT07560956
- Anderson-Fabry Disease Fitness Improvement TrainingRecruitingNCT07495410Not applicable
- Care Pathway for Patients With Fabry's Disease (Fabry-PATH)Not yet recruitingNCT07485660
- Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy PhenotypesRecruitingNCT07382128
- Novel Diagnostic and Prognostic Predictors in Fabry Cardiomyopathy: Proof of Concept in a Rare DiseaseNot yet recruitingNCT07351136
- Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance TechniquesRecruitingNCT07336394
- Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific TreatmentRecruitingNCT07277361
- Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR StudyRecruitingNCT07235709
- A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseRecruitingNCT07187440
- Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world SettingRecruitingNCT07109375
- Aortic Dimensions in Patients With Fabry DiseaseNot yet recruitingNCT06956573
- Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingRecruitingNCT06941025
- A Study of Patients With Fabry Disease (US Specific)RecruitingNCT06906367
- A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsRecruitingNCT06904261Phase 3
- Functional Capacity in Anderson-Fabry Disease PatientsRecruitingNCT06884358
- Efficacy and Safety of Enzyme Replacement Therapy in Patients With Fabry DiseaseEnrolling by invitationNCT06880250
- The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry DiseaseNot yet recruitingNCT06819514Phase 1/2
- Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac TransplantationRecruitingNCT06813443
- Italian Anderson Fabry Disease Cardiovascular RegistryRecruitingNCT06806813
- the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY DiseaseRecruitingNCT06776419
- Characterizing the Retinal Microvasculature in Patients with Fabry Disease: a Prospective Observational StudyRecruitingNCT06758648
- A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry PatientsRecruitingNCT06663358
- Cardiovascular Multimodality Imaging StudyRecruitingNCT06610019
- Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.RecruitingNCT06607471
- Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry DiseaseRecruitingNCT06539624Not applicable
- CVI Alterations in FD: a Prospective, Multicenter, Observational Cohort StudyRecruitingNCT06512571
- A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseaseRecruitingNCT06328608Phase 2/3
- Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY DiseaseRecruitingNCT06325488
- Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry DiseaseRecruitingNCT06270316Phase 1/2
- Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry DiseaseRecruitingNCT06207552Early Phase 1
- Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular HypertrophyRecruitingNCT06169358
- Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry DiseaseRecruitingNCT06114329Phase 2
- Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry DiseaseRecruitingNCT06081062Phase 3
- National Registry of Rare Kidney DiseasesRecruitingNCT06065852
- Assess Urine Biomarkers to Predict Nephropathy in Fabry DiseaseRecruitingNCT06065605
- Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry DiseaseRecruitingNCT05710692Phase 2/3
- Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry DiseaseRecruitingNCT05698901
- 4D-310 in Adults With Fabry Disease and Cardiac InvolvementRecruitingNCT05629559Phase 1/2
- Taiwan Associated Genetic and Nongenetic Small Vessel DiseaseRecruitingNCT05473637
- Fabry Exercise Intolerance StudyRecruitingNCT05413876
- ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening ProgramEnrolling by invitationNCT05368038
- A Study of Replagal in Children and Adults With Fabry Disease in IndiaRecruitingNCT05067868Phase 4
- Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRIRecruitingNCT04856059Not applicable
- Effect of Cannabinoids on Pain in Fabry Disease PatientsRecruitingNCT04820361Not applicable
- Impact of MIgalastat TheRApy on CaRdiac Function in patiEnts With Fabry's Cardiomyopathy (MIRACRE-Fabry Trial)RecruitingNCT04639999
- Long Duration Holter ECG in Fabry DiseaseRecruitingNCT04440254Not applicable
- A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingRecruitingNCT04252066
- Evaluation of HEArt invoLvement in Patients With FABRY DiseaseRecruitingNCT03362164
- Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease StudyRecruitingNCT01581424
- Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry DiseaseAvailableNCT01476163
- Canadian Fabry Disease Initiative (CFDI) National RegistryRecruitingNCT00455104
- Fabry Disease Registry & Pregnancy Sub-registryRecruitingNCT00196742
- A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of FabrazymeCompletedNCT06019728Phase 4Results posted
- Switch Over Study of Biosimilar Agalsidase Beta for Fabry DiseaseCompletedNCT05843916Phase 3Results posted
- PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV InfusionCompletedNCT05343715Phase 1Results posted
- A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry DiseaseCompletedNCT04974749Phase 3Results posted
- A Study of Replagal in Treatment-naïve Adults With Fabry DiseaseTerminatedNCT04840667Phase 3Results posted
- A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190TerminatedNCT04455230Phase 1/2Results posted
- A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.CompletedNCT04281537Results posted
- Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry DiseaseCompletedNCT04049760Phase 3Results posted
- Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)CompletedNCT04046224Phase 1/2Results posted
- A Fabry Disease Gene Therapy StudyTerminatedNCT04040049Phase 1/2Results posted
- Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry DiseaseCompletedNCT03566017Phase 3Results posted
- Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)CompletedNCT03500094Phase 3Results posted
- Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry DiseaseTerminatedNCT03454893Phase 1/2Results posted
- Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry DiseaseCompletedNCT03425539Phase 3Results posted
- Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 WeeksCompletedNCT03180840Phase 3Results posted
- Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)CompletedNCT03018730Phase 3Results posted
- Assessment of Small Fiber Neuropathy in Rare Diseases Using SudoscanCompletedNCT02985710Not applicableResults posted
- Evaluation of the Gastrointestinal Manifestation of Fabry's DiseaseCompletedNCT02798458Not applicableResults posted
- Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal FunctionCompletedNCT02795676Phase 3Results posted
- Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry DiseaseCompletedNCT02489344Phase 2Results posted
- Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry DiseaseCompletedNCT02228460Phase 2Results posted
- Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry DiseaseCompletedNCT02194985Phase 3Results posted
- Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry PatientsCompletedNCT02023086Results posted
- Extension Study of PRX-102 for up to 60 MonthsCompletedNCT01981720Phase 1/2Results posted
- Dose-ranging Study of PRX-102 in Adult Fabry Disease PatientsCompletedNCT01678898Phase 1/2Results posted
- A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase BetaCompletedNCT01650779Phase 4Results posted
- Open-Label Phase 3 Long-Term Safety Study of MigalastatTerminatedNCT01458119Phase 3Results posted
- Safety Study of Replagal® Therapy in Children With Fabry DiseaseCompletedNCT01363492Phase 2Results posted
- This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.CompletedNCT01304277Phase 2Results posted
- A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry DiseaseCompletedNCT01298141Phase 3Results posted
- Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry DiseaseCompletedNCT01218659Phase 3Results posted
- Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry DiseaseCompletedNCT01196871Phase 2Results posted
- Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry DiseaseCompletedNCT01124643Phase 3Results posted
- Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry DiseaseCompletedNCT00925301Phase 3Results posted
- Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry DiseaseCompletedNCT00864851Phase 3Results posted
- Severe Renal Disease Study in Fabry Patients Treated With FabrazymeTerminatedNCT00837824Phase 2Results posted
- A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe SymptomsCompletedNCT00701415Phase 3Results posted
- Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 StudyTerminatedNCT00526071Phase 2Results posted
- A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry DiseaseCompletedNCT00304512Phase 2Results posted
- A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseCompletedNCT00283959Phase 2Results posted
- A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseCompletedNCT00283933Phase 2Results posted
- Study of the Effects of Fabrazyme Treatment on Lactation and InfantsTerminatedNCT00230607Phase 4Results posted
- A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry DiseaseCompletedNCT00214500Phase 2Results posted
- A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry DiseaseCompletedNCT00196716Phase 2Results posted